SAN DIEGO, March 4 /PRNewswire/ -- Trega Biosciences, Inc. (Nasdaq: TRGA)
today announced that Isis Pharmaceuticals, Inc., will purchase combinatorial
libraries from Trega through its Chem.Folio(TM) program.
Under the terms of the agreement, Trega will give Isis non-exclusive
access to its small-molecule combinatorial libraries in exchange for an
up-front payment on each compound delivered. Isis also has the option to
license synthetic protocols for libraries from which active compounds are
identified. The specific financial terms of the agreement were not disclosed.
"We are delighted to add Isis Pharmaceuticals to our growing list of
partners, which includes Biogen, Parke-Davis and Chugai Biopharmaceuticals,"
said Michael G. Grey, Trega's President and Chief Executive Officer. "Our
Chem.Folio(TM) product is suitable for a wide range of pharmaceutical
companies as well as for companies like Isis, which are looking for diverse,
drug-like chemical libraries to use in their drug discovery efforts."
Chem.Folio provides customers access to novel, diverse combinatorial
chemistry libraries for the identification of biologically active compounds.
Trega Biosciences is a drug discovery company utilizing combinatorial
chemistry and other technologies to pursue the discovery of novel,
small-molecule drug therapies. The company leverages its technology platform
by entering into pharmaceutical alliances, which provide partners with access
to Trega's technologies in exchange for licensing fees and potential
milestones and royalties, or by establishing joint-discovery alliances with
pharmaceutical and biotechnology companies. Trega also uses its drug
discovery technologies in its internal development programs, which are focused
today on discovering small molecules acting on melanocortin receptors.
Melanocortins are a class of receptors which may be important in the treatment
of inflammatory and metabolic diseases.
Except for the historical information contained herein, the matters
discussed in this news release are forward-looking statements that involve
risks and uncertainties, including whether an extended collaboration will be
agreed to, any proposed product can be successfully formulated, scaled-up,
developed, and commercialized, whether regulatory approvals can be obtained,
the impact of competitive products and pricing, whether any corporate
collaborations or alliances will be successful, and other risks detailed from
time to time in Trega's Securities and Exchange Commission filings.
These forward-looking statements represent Trega's judgment as of the date of
this release. Actual results may differ materially from those projected.
Trega disclaims, however, any intent or obligation to update these forward-
looking statements.
Trega's releases are on the World Wide Web at http://www.trega.com and
PRNewswire's fax-on-demand service at 1-800-758-5804, extension 374050.
SOURCE Trega Biosciences, Inc.
 back to top
Company News On-Call:
http://www.prnewswire.com/comp/374050.html or fax,
800-758-5804, ext. 374050
CONTACT:
Vince Reardon, Director, Investor Relations
and Corporate Communications, Trega Biosciences, 619-410-6555, or
fax 619-410-6704, vreardon@trega.com
|
